In addition, the claims have been amended as set forth in the attachment herewith pursuant to 37 C.F.R § 1.121 so as to comply with the Office's restriction requirement of Group I compounds and to further define the invention. Claim 1 has also been amended to require that R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> represent hydrogen, and R<sup>8</sup> represents methyl. Support for this amendment can be found in the specification, for example, at page 16, lines 23-24. In addition, in claim 1, "q" has been amended to represent one. Support for this amendment can be found in original claim 6, which has now been cancelled. It is respectfully submitted that entry of the amendments submitted herewith introduces no new matter to the application.

Applicants respectfully submit that claims 1-5, 7-10, 14-16, 18 and 20 are in condition for examination. An early allowance of claims 1-5, 7-10, 14-16, 18 and 20 is kindly solicited.

Respectfully submitted,

Nelsen L. Lentz

Attorney for Applicants

Registration No. 38,537

Phone: 317-276-1207

Eli Lilly and Company Patent Division P. O. Box 6288

Indianapolis, Indiana 46285